CORRECTION - TARGET PRICE IS 45 cents

Quote






anonymous said:
REVENEW UP 80% IN PAST YEAR !!! THAT IS WHAT IS CALLED A REBOUND !!

STOCK MARKET MAY SOON TANK SO TAKE A HEDGE WITH ACOR !!
Click to expand...

Nonsense Habib,

That is what we call made up propaganda.

Your numbers are down internationally (if that were possible) and your numbers in the US are up slightly due to price increases. RGR even lowered revenue guidance (again).

you have OPEX of $95M and cash on hand of $26M. You are going to be out of business by next summer.
 






anonymous said:
Nonsense Habib,

That is what we call made up propaganda.

Your numbers are down internationally (if that were possible) and your numbers in the US are up slightly due to price increases. RGR even lowered revenue guidance (again).

you have OPEX of $95M and cash on hand of $26M. You are going to be out of business by next summer.
Click to expand...

Even sooner when you factor the spend on commercials… presented as an omnichannel campaign but actually mini commercials on streaming platforms … I estimate they can remain solvent until March 2024
 












anonymous said:
Even sooner when you factor the spend on commercials… presented as an omnichannel campaign but actually mini commercials on streaming platforms … I estimate they can remain solvent until March 2024
Click to expand...

those “streaming” mini commercials are such a load of crap. RGR knows there is no demand and horrible coverage for MeTooDopa so he chose a cheap, ineffective avenue to be able to say he is doing something.

Saying the marketing for MeTooDopa is omnichannel is like claiming the stock is dynamic or the company is rebounding. Total BS.

there are companies doing significant DTC for rare diseases that affect less than 200,000 in the US and RGR and his misfit COO and CCO couldn’t do it for a condition affecting more than 500,000?!

Of course the other products are novel, have data and bring something to the table…….
 






anonymous said:
those “streaming” mini commercials are such a load of crap. RGR knows there is no demand and horrible coverage for MeTooDopa so he chose a cheap, ineffective avenue to be able to say he is doing something.

Saying the marketing for MeTooDopa is omnichannel is like claiming the stock is dynamic or the company is rebounding. Total BS.

there are companies doing significant DTC for rare diseases that affect less than 200,000 in the US and RGR and his misfit COO and CCO couldn’t do it for a condition affecting more than 500,000?!

Of course the other products are novel, have data and bring something to the table…….
Click to expand...
Those streaming commercials are very effective. Was a great innovation. PR comes in many forms and the streaming compliments the CP effort !!
 
















































Top Bottom
Back
Quote